Stay updated on Pembrolizumab for High-Grade Neuroendocrine Carcinomas Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab for High-Grade Neuroendocrine Carcinomas Clinical Trial page.

Latest updates to the Pembrolizumab for High-Grade Neuroendocrine Carcinomas Clinical Trial page
- Check2 days agoChange DetectedThe web page has been updated from version 2.16.2 to version 2.16.3.SummaryDifference0.1%
- Check10 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check17 days agoChange DetectedThe web page has been updated to announce the modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, allowing API users to provide input. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.SummaryDifference1.0%
- Check24 days agoChange DetectedThe web page has been updated to version 2.16.0, replacing the previous version 2.15.2.SummaryDifference0.2%
- Check46 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check60 days agoChange DetectedThe page has been updated to reflect a new version of the study, with significant changes including the removal of detailed study objectives and inclusion criteria for a pilot study on pembrolizumab-based therapy for high-grade neuroendocrine carcinomas, while adding a new diagnosis and registry identifier.SummaryDifference54%
Stay in the know with updates to Pembrolizumab for High-Grade Neuroendocrine Carcinomas Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for High-Grade Neuroendocrine Carcinomas Clinical Trial page.